VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)
NCT ID: NCT02544425
Last Updated: 2020-10-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
27 participants
INTERVENTIONAL
2016-02-21
2021-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma
NCT00418535
Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma
NCT01238159
High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma
NCT02531841
Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL
NCT00504751
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
NCT00458731
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VIDL+ASCT
1. VIDL Induction (repeated 28 days) : VP-16, Ifosfamide, Dexamethasone, L-asparaginase
2. Peripheral blood stem cell mobilization:Etoposide
3. Conditioning regimen for autologous stem cell transplantation:Busulfan,Melphalan,Etoposide
Etoposide
Subjects will receive Etoposide 100 mg/m2 + 5% dextrose in water 500 mL intravenous over 90 mins D1-3 of VIDL chemotherapy. After that, Etoposide will be administered 375mg/m2 D1-2 with G-colony stimulating factor (10 ug/kg) injection in step of Peripheral Blood Stem Cell Collection. Also It will be administered 400mg/m2 on conditioning regimen.
Ifosfamide
It will be administered1.2g/m2 + 5% dextrose in water 100 mL intravenous over 1 hr D1-3
Dexamethasone
It will be administered 40mg/day PO or IV D1-3
L-asparaginase
It will be administered 4000 IU/m2 intramuscular D8, 10, 12, 14, 16, 18, 20
Busulfan
Conditioning regimen for autologous stem cell transplantation:
Busulfan 3.2 mg/kg D -8, -7, -6
Melphalan
Conditioning regimen for autologous stem cell transplantation:
Melphalan 70 mg/m2 D -3, -2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Etoposide
Subjects will receive Etoposide 100 mg/m2 + 5% dextrose in water 500 mL intravenous over 90 mins D1-3 of VIDL chemotherapy. After that, Etoposide will be administered 375mg/m2 D1-2 with G-colony stimulating factor (10 ug/kg) injection in step of Peripheral Blood Stem Cell Collection. Also It will be administered 400mg/m2 on conditioning regimen.
Ifosfamide
It will be administered1.2g/m2 + 5% dextrose in water 100 mL intravenous over 1 hr D1-3
Dexamethasone
It will be administered 40mg/day PO or IV D1-3
L-asparaginase
It will be administered 4000 IU/m2 intramuscular D8, 10, 12, 14, 16, 18, 20
Busulfan
Conditioning regimen for autologous stem cell transplantation:
Busulfan 3.2 mg/kg D -8, -7, -6
Melphalan
Conditioning regimen for autologous stem cell transplantation:
Melphalan 70 mg/m2 D -3, -2
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged between 19 and 65 years
* Previously untreated history
* Performance status: Eastern Cooperative Oncology Group 0-2
* Ann Arbor stage III and IV
* At least one in positron emission tomograph(PET)/CT positive lesion or in 2-dimensional computerized tomography
* mass lesions more than 2 cm by conventional CT or more than 1 cm by spiral CT
* Skin lesions or physically detected mass more than 2 cm
* Cardiac ejection fraction ≥ 45 % as measured by multiple gated acquisition scan(MUGA) or 2D echogram(ECHO) without clinically significant abnormalities
* Adequate liver functions: Transaminase (AST/ALT) \< 3 X upper normal value(or \< 5 x upper limit of normal in the presence of NK/T lymphoma involvement of the liver)
* Bilirubin \< 2 X upper normal value(or \< 5 x upper limit of normal in the presence of DLBCL involvement of the liver)
* Serum Creatinine \< 2.0 mg/dL
* Adequate bone marrow functions: hemoglobin ≥ 9 g/dL absolute neutrophil count (ANC) ≥ 1,500/μL and platelet count ≥ 75,000/μL, unless abnormalities are due to bone marrow involvement by lymphoma
* Expected life is more than 180 days (more than 6 months)
* A negative serum or urine pregnancy test prior to treatment must be available both for pre-menopausal women and for women who are \< 1years after the onset of menopause. Premenopausal women should be treated with appropriate contraception such as hormone contraception, intra-uterine device, spermicidal condom and etc. during and one month after the treatment.
* Voluntarily signed the informed consent including fully understand of clinical procedures and processing steps for the clinical trial
Exclusion Criteria
* Other subtypes non-Hodgkin's lymphoma than NK/T cell lymphoma
* Patients who have aggressive NK/T cell leukemia
* NK/T cell lymphoma with Primary Central Nervous System (CNS) involvement. However, patients who have only had prophylactic intrathecal chemotherapy against CNS disease are eligible.
* Patients with a known history of HIV seropositivity or hepatitis C virus (HCV) (+). Patients who have carrier hepatitis B virus (HBV) (+) are eligible. However, primary prophylaxis using antiviral agents is recommended for HBV carrier to prevent HBV reactivation during whole treatment period.
* Any other malignancies within the past 5 years except curatively treated non-melanoma skin cancer or in situ carcinoma of cervix uteri
* Pregnant or lactating women, women of childbearing potential not employing adequate contraception
* Other serious illness or medical conditions i. Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry ii. History of significant neurologic or psychiatric disorders including dementia or seizures iii. Active uncontrolled infection (viral, bacterial or fungal infection) iv. Other serious medical illnesses
* Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy.
* Serious allergy history for experimental drugs
* Patients who contraindication to the study drug use
19 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Won Seog Kim
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
won-Seog Kim, MD,Ph.D
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsung Medical Center
Seoul, Seoul, Korea, Republic of, South Korea
Samsung Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-05-035
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.